Camelot BioCapital

About Camelot BioCapital

Camelot is a venture platform focusing on biotech company creation. Our firm partners with inventors, research centers, and academic institutions to accelerate the development of novel therapeutic compounds. Leveraging deep industry relationships, including top scientific advisors, healthcare investment banks, CROs, investors, and patent attorneys, we specialize in advancing early to mid-stage treatments through the FDA pipeline with the goal of delivering life-changing therapies to patients in need. Our investment focus is centered on pre-seed and seed-stage opportunities in oncology, autoimmune, and inflammatory disorders. The Camelot leadership team has worked together for over 20 years, during which we have: - Raised over $2 billion in capital - Advanced more than 20 drug candidates into human clinical trials - Achieved 7 FDA drug approvals We minimize the inherent risks of traditional biotech investing through a differentiated model that includes: - A rigorous asset selection process, guided by our experienced scientific advisory board and investment committee - Maintaining a lean operating structure with a fractionally low burn rate - Strategic industry partnerships that allow us to source high-potential technologies and assemble expert drug development teams - A focus on synergistic asset development and partnering strategies to enhance value creation and streamline exits

View contact profiles from Camelot BioCapital